Researchers compared COVID-19 outcomes in rheumatoid arthritis patients treated with biologic vs conventional DMARDs.

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

Several factors — but not older age — increased infection risk with the use of non-TNF biologics following first-line ...

Health care resource use increased in patients with Sjögren disease during the year after diagnosis, especially among those with comorbid autoimmune disorders.

Findings point to importance of RSV vaccination in older patients with systemic autoimmune rheumatic diseases.

Disease activity and multimorbidity among patients in the US with PsA varied based on geographic region, socioeconomic deprivation, race, and gender.

“The true prevalence of nonadherence to DMARDs in RA is unknown, and the factors that are associated with nonadherence have not been clearly defined,” the authors note. “This is further complicated by ...

With the recent observance of World Arthritis Day, stakeholders highlight persistent barriers to coordinated, affordable care, emphasizing the need for improved access, preventive strategies, and ...

Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.

Paediatric specialists say arthritis in childhood is real, and its effects can be long-lasting if not recognised early.